Prevention of diabetes by administration of gnrh antagonists
CA 2435877 C · Owner: Children'S Mercy Hospital · Inventors: Jacobson, Jill D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for reducing the incidence or delaying the onset of diabetes in diabetes-susceptible mammals (e.g. mice rats, humans) is provided wherein , the mammals are treated with a gonadotropin-releasing hormone (GnRH) antagonist. Preferably, the antagonist is administered repeatedly over time by subcutaneous injection. A useful antagonist is Acetyl-.beta.-2-Napthyl-D-Ala- D-p-Chloro-Phe-.beta.3-Pyridyl-D-Ala-Ser-N.epsilon.-Nicotinoyl-Lys- N.epsilon.Nicotinoyl-D-Lys-Leu-N.epsilon.-Isopropyl-Lys-Pro-D-Ala-NH2. Other useful antagonists are Nal-Glu, PPI-149 and acryline.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 6, 2001 and granted February 22, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 6, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 6, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.